TTD | Drug: D06BDC

Drug General Information
Drug ID	D06BDC
Former ID	DIB019256
Drug Name	compound 15b
Drug Type	Small molecular drug
Indication	Discovery agent		Investigative	[528084]
Formula	C21H21N5O
InChI	InChI=1S/C21H21N5O/c27-12-4-10-25-14-23-16-8-7-15(13-19(16)25)20-18-6-3-11-26(18)24-21(20)17-5-1-2-9-22-17/h1-2,5,7-9,13-14,27H,3-4,6,10-12H2
InChIKey	SYCWRTUPLPDKDX-UHFFFAOYSA-N
PubChem Compound ID	10361101
PubChem Substance ID	15374322, 22720376, 33994124, 80602109, 103481832, 104068811, 180395100, 226704994, 243087895, 249565874
Target and Pathway
Target(s)	TGF-beta receptor type I	Target Info	Inhibitor	[528084]
	ZAK sterile alpha motif and leucine zipper containing kinase AZK	Target Info	Inhibitor	[528084]
	TGF-beta type II receptor	Target Info	Inhibitor	[528084]
KEGG Pathway	MAPK signaling pathway
	Cytokine-cytokine receptor interaction
	FoxO signaling pathway
	Endocytosis
	TGF-beta signaling pathway
	Osteoclast differentiation
	Hippo signaling pathway
	Adherens junction
	Chagas disease (American trypanosomiasis)
	Hepatitis B
	HTLV-I infection
	Pathways in cancer
	Colorectal cancer
	Pancreatic cancer
	Chronic myeloid leukemiahsa04010:MAPK signaling pathway
	Transcriptional misregulation in cancer
	Chronic myeloid leukemia
NetPath Pathway	FSH Signaling Pathway
NetPath Pathway	IL2 Signaling Pathway
PANTHER Pathway	TGF-beta signaling pathwayP00052:TGF-beta signaling pathway
Pathway Interaction Database	Glypican 1 network
	ALK1 signaling events
	Beta5 beta6 beta7 and beta8 integrin cell surface interactions
	TGF-beta receptor signalingglypican_1pathway:Glypican 1 network
	Beta3 integrin cell surface interactions
	Integrins in angiogenesis
	TGF-beta receptor signaling
Reactome	TGF-beta receptor signaling activates SMADs
	TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
	SMAD2/3 Phosphorylation Motif Mutants in Cancer
	SMAD2/3 MH2 Domain Mutants in Cancer
	TGFBR2 Kinase Domain Mutants in Cancer
	TGFBR1 KD Mutants in Cancer
	TGFBR1 LBD Mutants in CancerR-HSA-2173789:TGF-beta receptor signaling activates SMADs
	TGFBR1 LBD Mutants in Cancer
WikiPathways	TGF Beta Signaling Pathway
	p38 MAPK Signaling Pathway
	MAPK Signaling Pathway
	TGF beta Signaling Pathway
	Extracellular vesicle-mediated signaling in recipient cells
	Cardiac Hypertrophic Response
	Signaling by TGF-beta Receptor Complex
	Integrated Pancreatic Cancer Pathway
	Integrated Breast Cancer PathwayWP560:TGF Beta Signaling Pathway
	NRF2 pathway
	Nuclear Receptors Meta-Pathway
	miR-targeted genes in squamous cell - TarBase
	miR-targeted genes in muscle cell - TarBase
	miR-targeted genes in lymphocytes - TarBase
	miR-targeted genes in epithelium - TarBase
	miR-targeted genes in adipocytes - TarBase
	Integrated Breast Cancer Pathway
References
Ref 528084	J Med Chem. 2006 Mar 23;49(6):2138-42.Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7.
Ref 528084	J Med Chem. 2006 Mar 23;49(6):2138-42.Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.

Drug Information